NoviThera Initiates Key Animal Studies on Psoriasis Treatment
NoviThera ApS, a majority-owned subsidiary of Nordicus Partners Corporation (OTCQB: NORD), has embarked on significant studies aimed at developing new treatments for psoriasis. This innovative approach marks the first steps into animal studies to establish efficacy and biological proof of concept for a novel monoclonal antibody therapy dedicated to this inflammatory condition.
Understanding Psoriasis and Its Challenges
Psoriasis is a chronic auto-inflammatory disease that leads to rapid skin cell proliferation. Patients typically present with scaly, red plaques and experience discomfort and emotional distress. Traditional treatments often include topical therapies, phototherapy, and for more severe instances, biologics targeting specific immune pathways. However, the quest for new and effective treatments remains critical as current options do not work for everyone.
The Role of the Polypeptide in Psoriasis
Research indicates that psoriasis may be exacerbated by an endogenous polypeptide that promotes inflammation. This polypeptide, an antimicrobial cathelicidin produced by skin cells, plays a dual role in immune regulation. While it defends against pathogens, it can also heighten inflammation. By understanding the intricate balance between these effects, NoviThera aims to manipulate the polypeptide’s presence to diminish psoriasis symptoms.
Current Research Initiatives
NoviThera is actively engaged in two crucial preclinical studies. The first involves administering injections at psoriasis plaques in mice to test the efficacy of their proprietary monoclonal antibody. The outcome of this study will play a pivotal role in determining the next steps for clinical application.
Developing Humanized Mouse Models
The second study focuses on creating a humanized genetic mouse that can produce the polypeptide, a molecule not found in mice. This allows for a more accurate representation of human psoriasis and is essential for subsequent testing of therapies.
Future Possibilities
Following the current preclinical phases, NoviThera plans to move into toxicology studies within the next few years, with patient trials targeted for the near future. The exciting potential for a groundbreaking treatment looms ahead, paving the way for improved patient outcomes.
About NoviThera and Nordicus Partners Corporation
NoviThera is dedicated to pioneering innovative solutions in the treatment of psoriasis through its unique monoclonal antibody therapy. The leadership at NoviThera, under CEO Allan Wehnert, collaborates closely with Nordicus Partners Corporation, which specializes in supporting Nordic life science ventures in the U.S. market.
Nordicus is recognized as a one-of-a-kind business accelerator and holding entity focusing on Nordic life sciences. Their strategic acquisitions and robust experience in corporate finance enable them to better serve companies on their growth trajectories. The recent acquisitions of Orocidin A/S and Bio-Convert A/S highlight Nordicus's commitment to expanding innovative care solutions.
Contact Information
For further inquiries regarding investor relations, please contact:
Nordicus Investor Relations
info@nordicuspartners.com
For media inquiries, reach out to:
Ulveman & Børsting
kontakt@ulvemanborsting.com
Frequently Asked Questions
What is the focus of NoviThera's current research?
NoviThera is focused on initiating animal studies to assess the efficacy of a monoclonal antibody treatment for psoriasis.
How does the polypeptide affect psoriasis?
The polypeptide can exacerbate inflammation in psoriasis, but understanding its role may lead to improved treatments by controlling its levels.
What are the next steps after the animal studies?
NoviThera plans to conduct toxicity studies followed by trials in patients to evaluate the safety and effectiveness of their treatments.
Who leads NoviThera?
NoviThera is led by CEO Allan Wehnert, who has a vision for innovative treatments in the field of dermatology.
What is the role of Nordicus Partners Corporation?
Nordicus Partners Corporation supports the development and market establishment of Nordic life science companies, enhancing their growth and potential in the U.S.
